Login/Create Account
Orphan Drugs in Germany: Funding and Insurance Coverage for Rare Diseases
What are “orphan drugs”?
“Orphan drugs” are medicines developed specifically to treat rare diseases (Seltene Erkrankungen). These are conditions that:
-
affect fewer than 5 out of every 10,000 people in the European Union.
They include diseases such as:
-
cystic fibrosis
-
inherited muscular dystrophies
-
certain rare types of cancer
-
hereditary metabolic disorders
How are these drugs funded in Germany?
Although orphan drugs are often very expensive, the German healthcare system ensures their funding through:
1. Statutory health insurance (Gesetzliche Krankenversicherung – GKV)
✅ Most orphan drugs are automatically covered by statutory health insurance.
-
The patient usually only needs a prescription from a specialist.
-
The drug is reimbursed at 100% or subject to a small co-payment (Zuzahlung).
2. Compensation for manufacturers
Because research and development costs are high while the number of patients is low:
-
Germany generally allows relatively high prices for orphan drugs to compensate manufacturers’ investments.
-
Some companies receive additional research support from the European Union (EU Orphan Incentives).
How are orphan drugs approved in Germany?
They are subject to European medicines legislation and receive orphan drug designation from:
-
the European Medicines Agency (EMA).
This often results in:
-
accelerated approval procedures
-
facilitated access to funding and reimbursement.
In Germany, orphan drugs are usually exempt from the standard health-economic evaluation (AMNOG procedure), unless their annual sales exceed 50 million euros.
Why are they so expensive?
-
The number of patients is very small → development costs cannot be spread across a large population.
-
Clinical trials are rare, difficult to conduct and very costly.
-
Development often targets urgent medical needs where no adequate treatment exists (unmet medical needs).
Despite this, orphan drugs are funded because they represent a crucial hope for patients who have no other therapeutic options.
Can a patient request a drug that is not (yet) listed?
Yes, in certain cases:
-
The specialist physician must submit a detailed medical report.
-
It must be demonstrated that there are no suitable alternative treatments.
The health insurance fund then reviews the case and may grant approval.
In rare cases, requests are rejected. Then an appeal is possible via:
-
the MDK (Medical Service of the Health Insurance)
-
or, if necessary, through legal action at the Social Court (Sozialgericht).
Statistics
-
More than 130 orphan drugs are currently approved in Germany.
-
They provide treatments for more than 300 rare diseases.
-
Covering these therapies costs the health system several billion euros per year, but is regarded as medically and ethically necessary.
Summary
Question – Answer
Are orphan drugs covered in Germany?
✅ Yes, in most cases they are covered almost completely by health insurance funds.
Why are they considered so expensive?
Because there are very few patients and development and trial costs are extremely high.
Are there special rules for their assessment?
Yes. They are generally exempt from the AMNOG evaluation unless their annual sales exceed 50 million euros.
Is it possible to appeal if coverage is denied?
✅ Yes, via the treating physician, the MDK or by filing a claim with the Social Court.
The editorial team of the website strives to provide accurate information based on thorough research and consultation of multiple sources. Nevertheless, errors may occur or some details may remain uncertain. The information in this article should therefore be regarded as an initial point of reference. For definitive and legally binding information, you should always consult the competent authorities and specialist institutions.
